-
Je něco špatně v tomto záznamu ?
Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications
B. Ostadal, P. Ostadal,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
Free Medical Journals
od 1968 do Před 1 rokem
PubMed Central
od 1968 do 2020
Europe PubMed Central
od 1968 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2002-01-01 do Před 1 rokem
Wiley Free Content
od 1997 do Před 1 rokem
PubMed
23750471
DOI
10.1111/bph.12270
Knihovny.cz E-zdroje
- MeSH
- akutní koronární syndrom farmakoterapie metabolismus patofyziologie MeSH
- androgeny metabolismus MeSH
- estrogeny metabolismus MeSH
- ischemická choroba srdeční farmakoterapie metabolismus patofyziologie MeSH
- kardiovaskulární látky terapeutické užití MeSH
- lidé MeSH
- medicína založená na důkazech * MeSH
- myokard metabolismus MeSH
- náchylnost k nemoci MeSH
- pohlavní dimorfismus MeSH
- reperfuzní poškození myokardu prevence a kontrola MeSH
- srdce účinky léků patofyziologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Ischaemic heart disease (IHD) is the most frequent cause of mortality among men and women. Many epidemiological studies have demonstrated that premenopausal women have a reduced risk for IHD compared with their male counterparts. The incidence of IHD in women increases after menopause, suggesting that IHD is related to declining oestrogen levels. Experimental observations have confirmed the results of epidemiological studies investigating sex-specific differences in cardiac tolerance to ischaemia. Female sex appears also to favourably influence cardiac remodelling after ischaemia/reperfusion injury. Furthermore, sex-related differences in ischaemic tolerance of the adult myocardium can be influenced by interventions during the early phases of ontogenetic development. Detailed mechanisms of these sex-related differences remain unknown; however, they involve the genomic and non-genomic effects of sex steroid hormones, particularly the oestrogens, which have been the most extensively studied. Although the protective effects of oestrogen have many potential therapeutic implications, clinical trials have shown that oestrogen replacement in postmenopausal women may actually increase the incidence of IHD. The results of these trials have illustrated the complexity underlying the mechanisms involved in sex-related differences in cardiac tolerance to ischaemia. Sex-related differences in cardiac sensitivity to ischaemia/reperfusion injury may also influence therapeutic strategies in women with acute coronary syndrome. Women undergo coronary intervention less frequently and a lower proportion of women receive evidence-based therapy compared with men. Although our understanding of this important topic has increased in recent years, there is an urgent need for intensive experimental and clinical research to develop female-specific therapeutic strategies. Only then we will be able to offer patients better evidence-based treatment, a better quality of life and lower mortality.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15008614
- 003
- CZ-PrNML
- 005
- 20150313102044.0
- 007
- ta
- 008
- 150306s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bph.12270 $2 doi
- 035 __
- $a (PubMed)23750471
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Ostadal, B $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 245 10
- $a Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications / $c B. Ostadal, P. Ostadal,
- 520 9_
- $a Ischaemic heart disease (IHD) is the most frequent cause of mortality among men and women. Many epidemiological studies have demonstrated that premenopausal women have a reduced risk for IHD compared with their male counterparts. The incidence of IHD in women increases after menopause, suggesting that IHD is related to declining oestrogen levels. Experimental observations have confirmed the results of epidemiological studies investigating sex-specific differences in cardiac tolerance to ischaemia. Female sex appears also to favourably influence cardiac remodelling after ischaemia/reperfusion injury. Furthermore, sex-related differences in ischaemic tolerance of the adult myocardium can be influenced by interventions during the early phases of ontogenetic development. Detailed mechanisms of these sex-related differences remain unknown; however, they involve the genomic and non-genomic effects of sex steroid hormones, particularly the oestrogens, which have been the most extensively studied. Although the protective effects of oestrogen have many potential therapeutic implications, clinical trials have shown that oestrogen replacement in postmenopausal women may actually increase the incidence of IHD. The results of these trials have illustrated the complexity underlying the mechanisms involved in sex-related differences in cardiac tolerance to ischaemia. Sex-related differences in cardiac sensitivity to ischaemia/reperfusion injury may also influence therapeutic strategies in women with acute coronary syndrome. Women undergo coronary intervention less frequently and a lower proportion of women receive evidence-based therapy compared with men. Although our understanding of this important topic has increased in recent years, there is an urgent need for intensive experimental and clinical research to develop female-specific therapeutic strategies. Only then we will be able to offer patients better evidence-based treatment, a better quality of life and lower mortality.
- 650 _2
- $a akutní koronární syndrom $x farmakoterapie $x metabolismus $x patofyziologie $7 D054058
- 650 _2
- $a androgeny $x metabolismus $7 D000728
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kardiovaskulární látky $x terapeutické užití $7 D002317
- 650 _2
- $a náchylnost k nemoci $7 D004198
- 650 _2
- $a estrogeny $x metabolismus $7 D004967
- 650 12
- $a medicína založená na důkazech $7 D019317
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a srdce $x účinky léků $x patofyziologie $7 D006321
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ischemická choroba srdeční $x farmakoterapie $x metabolismus $x patofyziologie $7 D017202
- 650 _2
- $a reperfuzní poškození myokardu $x prevence a kontrola $7 D015428
- 650 _2
- $a myokard $x metabolismus $7 D009206
- 650 _2
- $a pohlavní dimorfismus $7 D012727
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ostadal, P
- 773 0_
- $w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 171, č. 3 (2014), s. 541-54
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23750471 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150306 $b ABA008
- 991 __
- $a 20150313102323 $b ABA008
- 999 __
- $a ok $b bmc $g 1065887 $s 891414
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 171 $c 3 $d 541-54 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
- LZP __
- $a Pubmed-20150306